Global Sevelamer Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Sevelamer Market Research Report 2024
Sevelamer (rINN) is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is currently marketed by Sanofi under the trade names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate).
According to Mr Accuracy reports new survey, global Sevelamer market is projected to reach US$ 337.1 million in 2029, increasing from US$ 220 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Sevelamer market research.
Key manufacturers engaged in the Sevelamer industry include Sanofi, Impax Laboratories, InvaGen Pharmaceuticals, Dr. Reddy's Laboratories, Aurobindo Pharma and Amneal Pharmaceuticals, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Sevelamer were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Sevelamer market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sevelamer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Sanofi
Impax Laboratories
InvaGen Pharmaceuticals
Dr. Reddy's Laboratories
Aurobindo Pharma
Amneal Pharmaceuticals
Segment by Type
Tablet
Oral Suspension
Adult
Pediatric
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Sevelamer report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Sevelamer market is projected to reach US$ 337.1 million in 2029, increasing from US$ 220 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Sevelamer market research.
Key manufacturers engaged in the Sevelamer industry include Sanofi, Impax Laboratories, InvaGen Pharmaceuticals, Dr. Reddy's Laboratories, Aurobindo Pharma and Amneal Pharmaceuticals, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Sevelamer were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Sevelamer market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sevelamer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sanofi
Impax Laboratories
InvaGen Pharmaceuticals
Dr. Reddy's Laboratories
Aurobindo Pharma
Amneal Pharmaceuticals
Segment by Type
Tablet
Oral Suspension
Segment by Application
Adult
Pediatric
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Sevelamer report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source